Sagimet Biosciences Inc. (SGMT)
NASDAQ: SGMT · Real-Time Price · USD
7.87
-0.83 (-9.54%)
At close: Jun 27, 2025, 4:00 PM
7.75
-0.12 (-1.51%)
After-hours: Jun 27, 2025, 7:56 PM EDT
Sagimet Biosciences Employees
Sagimet Biosciences had 14 employees as of December 31, 2024. The number of employees increased by 4 or 40.00% compared to the previous year.
Employees
14
Change (1Y)
4
Growth (1Y)
40.00%
Revenue / Employee
n/a
Profits / Employee
-$4,079,571
Market Cap
253.38M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 14 | 4 | 40.00% |
| Dec 31, 2023 | 10 | 0 | - |
| Dec 31, 2022 | 10 | 3 | 42.86% |
| Dec 31, 2020 | 7 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
SGMT News
- 19 days ago - Sagimet Biosciences to Host Virtual KOL Event, “A New Mechanism of Action in Treating Acne: Update on Positive Phase 3 Denifanstat Trial for the Treatment of Moderate to Severe Acne” on June 16, 2025 - GlobeNewsWire
- 23 days ago - Sagimet: Positive China Partner Acne Vulgaris Data Bodes Well For TVB-3567 - Seeking Alpha
- 24 days ago - Sagimet Biosciences Announces Positive Phase 3 Results for Denifanstat for the Treatment of Moderate-to-Severe Acne from Partner Ascletis - GlobeNewsWire
- 5 weeks ago - Sagimet Biosciences to Host Virtual KOL Event, “Evaluating the Synergistic Potential of a Combination of Denifanstat and Resmetirom for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH)” on May 29, 2025 - GlobeNewsWire
- 7 weeks ago - Sagimet Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates - GlobeNewsWire
- 3 months ago - Sagimet Biosciences Reports Full Year 2024 Financial Results and Provides Corporate Updates - GlobeNewsWire
- 3 months ago - Sagimet Biosciences Announces Clearance of IND for FASN Inhibitor TVB-3567, to be Developed for the Treatment of Acne - GlobeNewsWire
- 4 months ago - Sagimet Biosciences' Denifanstat Should Be Worth More Today - Seeking Alpha